SCHEMBL5638695

SCHEMBL5638695

O=C(O)N[C@H]1CCCCN(Cc2cccnc2)C1=O

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 1/20 0.53
▸ POLB P06746 1/20 0.53
▸ NPY1R P25929 1/20 0.49
▸ ALDH1A1 P00352 2/20 0.49
▸ ACE P12821 3/20 0.47
▸ MME P08473 1/20 0.47
▸ APP P05067 1/20 0.47
▸ MAPT P10636 1/20 0.47
▸ HTT P42858 1/20 0.47
▸ SIGMAR1 Q99720 1/20 0.47
▸ RAMP1 O60894 2/20 0.46
▸ CALCRL Q16602 2/20 0.46
▸ SRC P12931 2/20 0.46
▸ CHRM2 P08172 1/20 0.46
▸ CHRM1 P11229 1/20 0.46
▸ CHRM3 P20309 1/20 0.46
▸ CHRNB2 P17787 1/20 0.46
▸ CHRNA4 P43681 1/20 0.46
▸ CASP1 P29466 1/20 0.46
▸ FNTA P49354 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5637435 0.87 NPY1R (0.58) NPY1RACEMMEAPPRAMP1
SCHEMBL5638151 0.86 SRC (0.49) KDM4ENPY1RALDH1A1ACEMME
SCHEMBL14171424 0.85 KDM4E (0.50) KDM4EPOLBNPY1RALDH1A1MAPT
SCHEMBL12525774 0.84 KDM4E (0.47) KDM4EPOLBNPY1RALDH1A1APP
SCHEMBL5638395 0.83 CHRNB2 (0.47) KDM4EPOLBALDH1A1MAPTHTT
SCHEMBL5638402 0.83 CHRNB2 (0.47) KDM4EPOLBNPY1RALDH1A1MAPT
SCHEMBL7950295 0.80 SRC (0.67) NPY1RAPPSRC
SCHEMBL5637803 0.79 SRC (0.52) NPY1RACEMMEAPPHTT
SCHEMBL12493548 0.78 CHRNB2 (0.52) KDM4EPOLBALDH1A1MAPTHTT
SCHEMBL5638492 0.78 CHRNB2 (0.52) KDM4EPOLBALDH1A1MAPTHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7220856-B2 Substituted quinoline CCR5 receptor antagonists SCHERING AKTIENGESELLSCHAFT (DE) 2007-05-22 — — US disclosed
EP-1534681-A1 SUBSTITUTED QUINOLINE CCR5 RECEPTOR ANTAGONISTS SCHERING AKTIENGESELLSCHAFT (DE) 2005-06-01 — — EP disclosed
US-20040072818-A1 Substituted quinoline CCR5 receptor antagonists SCHERING AKTIENGESELLSCHAFT (DE) 2004-04-15 — — US disclosed
WO-2004002960-A1 SUBSTITUTED QUINOLINE CCR5 RECEPTOR ANTAGONISTS SCHERING AKTIENGESELLSCHAFT (DE) 2004-01-08 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040072818-A1 Substituted quinoline CCR5 receptor antagonists CCR5, CXCR3, CCR2 KDM4E 3993/4885POLB 2325/4885NPY1R 265/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback